Crescent Biopharma CBIO
NASDAQ CBIO
$14.20 +0.28 (+2.05%)
As of: Nov 11, 2026 · 1:51 PM EST

Crescent Biopharma (CBIO) Return on Capital Employed [ROCE] (2014 - 2026)

Updated

Crescent Biopharma (CBIO) posted Return on Capital Employed [ROCE] of -97.72% for Q2 2026, up 0.30 percentage points from -98.02% a year earlier but down 18.34 percentage points from the prior quarter.

Analysis

Crescent Biopharma (CBIO) Return on Capital Employed [ROCE] (2014 - 2026) Analysis & Trends

For FY2025, Crescent Biopharma's Return on Capital Employed [ROCE] came in at -149.81%, down 20.04 percentage points from FY2024.

  • Annual Return on Capital Employed [ROCE] has declined for seven consecutive years, with a five-year change of -113.78 percentage points (FY2020 to FY2025).
  • In prior years, Crescent Biopharma's Return on Capital Employed [ROCE] was -129.78% in FY2024 (-35.65 pp), -94.12% in FY2023 (-20.28 pp), -73.84% in FY2022 (-14.41 pp) and -59.43% in FY2021 (-23.40 pp).
  • Quarterly Return on Capital Employed [ROCE] has run from a low of -311.01% in Q4 2024 to a high of -57.83% in Q3 2021 over five years.
  • On a year-over-year basis, Return on Capital Employed [ROCE] has increased in each of the last five quarters, with an average year-over-year change of +13.94 percentage points over the last eight quarters.
  • The strongest year-over-year quarter for Return on Capital Employed [ROCE] in the past five years was Q1 2026, with a gain of 212.06 percentage points; the weakest was Q4 2024, with a drop of 218.43 percentage points.
  • According to Business Quant data, Return on Capital Employed [ROCE] for the three prior quarters was -79.38% (Q1 2026), -99.62% (Q4 2025) and -61.41% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 35.41%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 17.52%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 21.60%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.65%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.91%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 17.37%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -6.15%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 11.32%
10 Crescent Biopharma 386.36 Mn -320.93 Mn - -97.72%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -97.72%
Mar 31, 2026 -79.38%
Dec 31, 2025 -99.62%
Sep 30, 2025 -61.41%
Jun 30, 2025 -98.02%
Mar 31, 2025 -291.44%
Dec 31, 2024 -311.01%
Sep 30, 2024 -268.78%
Jun 30, 2024 -163.80%
Mar 31, 2024 -114.46%
Dec 31, 2023 -92.58%
Sep 30, 2023 -78.85%
Jun 30, 2023 -66.77%
Mar 31, 2023 -81.46%
Dec 31, 2022 -105.33%
Sep 30, 2022 -102.75%
Jun 30, 2022 -97.60%
Mar 31, 2022 -84.96%
Dec 31, 2021 -71.03%
Sep 30, 2021 -57.83%
API Access

Crescent Biopharma Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=CBIO&period=max&api_key=YOUR_API_KEY